| Trial ID: | L5013 |
| Source ID: | NCT00732121
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Bone Turnover in Type 2 Diabetes Patients
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Sitagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change from baseline in the integrated response to the mixed meal test of markers of bone turnover following 8 weeks of treatment with sitagliptin vs. placebo., 8 weeks per subject | Secondary: Change in the active GIP in response to the mixed meal test, 8 weeks|Change in the active GLP-1 in response to the mixed meal test., 8 weeks|Change in the active GLP-2 in response to the mixed meal test., 8 weeks|Change in glucose response during the mixed meal test., 8 weeks|Change in insulin secretion during the mixed meal test., 8 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Vermont | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2008-08
|
| Completion Date: |
2010-08
|
| Results First Posted: |
|
| Last Update Posted: |
2010-06-28
|
| Locations: |
University of Vermont, South Burlington, Vermont, 05403, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00732121
|
